Evidence map›Paper›PMID 36997937›Full record

ArticleJournal of neuroinflammation2023

Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.

Ramona Miske, Madeleine Scharf, Kathrin Borowski, Nicole Rieckhoff, Bianca Teegen, Yvonne Denno, Christian Probst, Kersten Guthke, Ieva Didrihsone, Brigitte Wildemann and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Identification of DAGLA as an autoantibody target in cerebellar ataxia.Journal of neurology, neurosurgery, and psychiatry · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Ramona Miske *Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.
Madeleine Scharf *Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany. m.scharf@euroimmun.de.
Kathrin BorowskiClinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.
Nicole RieckhoffInstitute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.
Bianca TeegenClinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.
Yvonne DennoInstitute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.
Christian ProbstInstitute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.
Kersten GuthkeDepartment of Neurology, Städtisches Klinikum Görlitz, Görlitz, Germany.
Ieva DidrihsoneDepartment of Neurology, Hermann-Josef-Krankenhaus, Erkelenz, Germany.
Brigitte WildemannMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Klemens RuprechtDepartment of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Lars KomorowskiInstitute for Experimental Immunology, affiliated to EUROIMMUN AG, Lübeck, Germany.
Sven JariusMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.
Euroimmun Medizinische Labordiagnostika (Germany) · DEHeidelberg University · DEHermann-Josef-Krankenhaus Erkelenz · DEHumboldt-Universität zu Berlin · DEKlinikum Görlitz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeptins are cytoskeletal proteins with filament forming capabilities, which have multiple roles during cell division, cellular polarization, morphogenesis, and membrane trafficking. Autoantibodies against septin-5 are associated with non-paraneoplastic cerebellar ataxia, and autoantibodies against septin-7 with encephalopathy with prominent neuropsychiatric features. Here, we report on newly identified autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia. We also propose a strategy for anti-septin autoantibody determination.

methodsSera from three patients producing similar immunofluorescence staining patterns on cerebellar and hippocampal sections were subjected to immunoprecipitation followed by mass spectrometry. The identified candidate antigens, all of which were septins, were expressed recombinantly in HEK293 cells either individually, as complexes, or combinations missing individual septins, for use in recombinant cell-based indirect immunofluorescence assays (RC-IIFA). Specificity for septin-3 was further confirmed by tissue IIFA neutralization experiments. Finally, tumor tissue sections were analyzed immunohistochemically for septin-3 expression.

resultsImmunoprecipitation with rat cerebellum lysate revealed septin-3, -5, -6, -7, and -11 as candidate target antigens. Sera of all three patients reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of 149 healthy control sera was similarly reactive. In RC-IIFAs the patient sera recognized only cells expressing septin-3, individually and in complexes. Incubation of patient sera with five different septin combinations, each missing one of the five septins, confirmed the autoantibodies' specificity for septin-3. The tissue IIFA reactivity of patient serum was abolished by pre-incubation with HEK293 cell lysates overexpressing the septin-3/5/6/7/11 complex or septin-3 alone, but not with HEK293 cell lysates overexpressing septin-5 as control. All three patients had cancers (2 × melanoma, 1 × small cell lung cancer), presented with progressive cerebellar syndromes, and responded poorly to immunotherapy. Expression of septin-3 was demonstrated in resected tumor tissue available from one patient.

conclusionsSeptin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Based on our findings, RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex may serve as a screening tool to investigate anti-septin autoantibodies in serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single septins.

Indexed as

AutoantibodiesAutoimmunityCerebellar AtaxiaAnimalsHEK293 CellsHumansNeuronsRatsSeptinsAutoantibodiesseptin 3SeptinsAutoantibodiesAutoimmune cerebellar ataxiaAutoimmune encephalitisAutoimmunityCerebellitisCerebellumImmunoglobulin GImmunoprecipitationMelanomaParaneoplastic cerebellar degenerationParaneoplastic neurological syndromeSeptin-11Septin-3Septin-5Septin-6Septin-7SeptinsSmall-cell lung cancer

Identifiers

PMID36997937
PMCPMC10061979
OpenAlexW4361272904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.